Johnson & Johnson announced new 52-week Phase 3 data for ICOTYDE, an oral peptide treatment for moderate-to-severe plaque psoriasis, showing nearly 50% of adults and 60% of adolescents achieved complete skin clearance. The studies, ICONIC-ADVANCE 1 and 2 and ICONIC-LEAD, demonstrated sustained efficacy and a favorable safety profile with no new safety concerns. ICOTYDE blocks the IL-23 receptor, a key driver in psoriasis inflammation, and offers a once-daily pill option. These results highlight ICOTYDE's potential as a transformative first-line systemic therapy for psoriasis across age groups.
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
Genmab announced that DARZALEX (daratumumab) achieved net trade sales of $4.207 billion globally in Q2 2026, with $2.435 billion from the U.S. and $1.772 billion from other regions. Genmab earns royalties on these worldwide sales through its licensin...
Johnson & Johnson is set to report its Q2 2026 earnings with analysts expecting earnings per share of $2.85 and revenue of $25.02 billion, both higher than the previous year. The company has a strong track record of beating revenue estimates and its ...
Johnson & Johnson will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.06 billion, up from last year. Analysts from RBC Capital and TD Cowen have maintained positive ratings and raised price ...
